The Law Offices of Frank R. Cruz has filed a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR), alleging the company concealed material changes to its statistical analysis plan for its lead drug candidate, deramiocel. The suit, captioned Nkamga v. Capricor Therapeutics, Inc., et al., was filed in the United States District Court for the Southern District of California on July 30, 2026. It targets investors who acquired Capricor securities between December 17, 2025 and July 26, 2026, claiming they suffered losses due to materially false statements regarding the company’s regulatory prospects and clinical data integrity.

The legal action follows a series of adverse developments in late July 2026 that triggered a sharp decline in Capricor’s share price. On July 27, 2026, the U.S. Food and Drug Administration (FDA) released briefing documents ahead of its July 29 advisory committee (AdCom) meeting for the Biologics License Application (BLA). The documents revealed that Capricor had altered its pre-specified statistical analysis plan (SAP) without prior FDA review or agreement. The final SAP was created just one day before the clinical data was unblinded. The FDA stated it did not consider the conversion of raw change to percent change and back to raw change scientifically justified, labeling the analyses as post-hoc and exploratory. Consequently, the FDA concluded that the benefit-risk assessment for deramiocel appeared unfavorable due to a lack of evidence of effectiveness.

Market Reaction and Regulatory Outcome

On July 27, 2026, Capricor’s stock fell $12.70, or 64%, to close at $7.00 per share on unusually heavy trading volume. The situation worsened on July 29, 2026, when the AdCom met to discuss the Deramiocel BLA. The next day, Medscape reported that the panel relied on SAP version 1.1 as the prespecified plan and voted 9-3 in a non-binding vote to conclude that available evidence did not support the efficacy of deramiocel for treating Duchenne muscular dystrophy-associated cardiomyopathy. Following this news, Capricor’s stock fell an additional $2.38, or 36%, to close at $4.19 per share on July 30, 2026.

Allegations of Misleading Statements

The complaint alleges that throughout the class period, defendants failed to disclose material adverse facts about the company’s business operations and prospects. Specifically, the lawsuit asserts that Capricor did not reveal:

• That the company adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel.
• That the FDA had not agreed to those changes before the company resubmitted the Deramiocel BLA.
• That there was a significant risk the FDA could conclude the clinical results did not provide substantial evidence of effectiveness.
• That there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy.

The claims are brought under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint argues that positive statements made by the company regarding its business prospects were misleading and lacked a reasonable basis given the undisclosed risks associated with the post-hoc data analysis.

What This Means for Investors

This litigation highlights severe scrutiny surrounding Capricor Therapeutics’ clinical trial conduct and regulatory transparency. The FDA’s rejection of the primary statistical analysis plan undermines the foundational evidence required for drug approval, casting doubt on the viability of deramiocel as a treatment for Duchenne muscular dystrophy. For shareholders within the defined class period, this lawsuit presents a potential avenue for recovery if the court finds merit in the claims of material misrepresentation. Investors are notified that they have 60 days from the date of the notice to move the court to serve as lead plaintiff. Those wishing to inquire about potentially pursuing claims are directed to contact The Law Offices of Frank R. Cruz.

Bloom Energy (NYSE: BE) has raised its financial guidance for fiscal year 2026, projecting higher adjusted earnings per share (EPS) and sales than previously anticipated and above current analyst estimates. The updated outlook reflects stronger-than-expected demand for the company's clean energy solutions. By lifting both top-line revenue targets and profitability metrics, Bloom Energy signals confidence in its operational execution and market positioning for the remainder of the fiscal period.

The revised adjusted EPS guidance for FY2026 stands at $2.55-$2.85, a significant increase from the prior range of $1.85-$2.25. This new midpoint exceeds the consensus analyst estimate of $2.15, indicating that management expects robust profit generation capabilities. The upward revision suggests improved margin dynamics or higher volume realization than initially modeled by investors.

On the revenue front, Bloom Energy increased its FY2026 sales guidance from $3.400 billion-$3.800 billion to $3.900 billion-$4.200 billion. This updated range also clears the market expectation of $3.721 billion. The expansion of the revenue band highlights accelerated order intake or faster deployment cycles within the company's core business segments.

Guidance Revisions

What the Numbers Show

The simultaneous upgrade in both revenue and earnings per share indicates that the growth is likely driven by operational leverage rather than just volume increases. With the revised EPS floor ($2.55) now exceeding the previous ceiling ($2.25), the company is forecasting a material improvement in profitability efficiency. Beating the consensus estimates on both metrics reduces downside risk for shareholders and may prompt analysts to re-evaluate valuation multiples for the stock.